gvtcx

NP47923b Tocilizumab

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£92,000,000
Statuscomplete
Category (CPV) 33600000
RegionScotland
Deadline21 Nov 2023
Procedureopen
OCIDocds-h6vhtk-040dc3

Awards (9)

This procurement was awarded to 9 suppliers. Values shown are per-award; the notice total is £92,000,000.

SupplierValueDateStatus
AbbVie Ltd shared · · active
Alexion Rare Disease part of Astra Zeneca shared · · active
Amgen Ltd shared · · active
Biogen Idec Ltd shared · · active
Celltrion Healthcare United Kingdom Limited shared · · active
Fresenius Kabi Limited shared · · active
Roche Products Ltd shared · · ·
Samsung Bioepis shared · · active
Sandoz shared · · active

description

Supply of tocilizumab to NHS Scotland.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
20 Oct 2023 Contract notice (F02) Earlier regulations 031051-2023
7 Feb 2024 Contract award notice (F03) Earlier regulations 003972-2024
7 Feb 2024 Contract award notice (F03) Earlier regulations 003971-2024
7 Feb 2024 Contract award notice (F03) Earlier regulations 003970-2024

more from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.